2 • 投资建议及推荐标的：1）推荐高中扩容。推荐：天立国际控股、学大教育。情绪价值消费结构景气。推荐：老铺黄金、潮宏基，受益标的： 曼卡龙。2）AI＋主题推荐：AI眼镜（康耐特光学、博士眼镜）、AI电商（小商品城）、AI玩具（孩子王）。3）低估值个股推荐：行动教 育、重庆百货、大商股份、周大福、百胜中国等。 • 政策加码，高中教育扩容。1）高中教育行业还有7-8年人口红利期。高中段适龄人口出生日期约为2008-2010年（15-17岁）、义务教育阶段 为2014-2019年（6-14岁）、学龄前为2020-2025年（0-5岁），预计高中段教育行业仍有近7-8年的稳定人口需求。 2）政策支持高中阶段教 育扩容，从职普分流到职普融合。中国高中教育普及率显著提升，但仍落后于发达国家。中国普通高中毕业生数占适龄人口比例逐步提高， 近年来已接近发达国家水平。 • 情绪与体验消费产业发展加速，传统需求迎来新供给。1）情绪价值与体验消费切中需求痛点，正在快速兑现商业价值。以IP潮玩为代表的 产业本质消费的是符号与内容价值，核心驱动力是不同社会阶段下底层心里诉求的更迭。2）黄金品类工艺附加值提升，消费属性提升驱动 市场持 ...

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 今 日 聚 焦 【策略】以稳致远——2025年6月五维行业比较观点 6月行业配置观点：预计市场风格将偏向防御与低估值板块。结合我们对于6月主观因素的判断，五维行业 比较框架视角下，预计市场风格将偏向防御与低估值板块，煤炭、公用事业、银行、非银金融、建筑装 饰、石油石化等行业得分较高，未来或值得投资者重点关注。 （张宇生/王国兴） 2 025- 06-03 您可点击今日推送内容的第1条查看 【金工】基金抱团加强，PB-ROE-50组合超额收益显著——金融工程量化月报20250603 截至2025年5月30日，沪深300上涨家数占比指标最近一个月环比上月上升，上涨家数占比指标高于50%， 市场情绪较高；从动量情绪指标走势来看，近一月快线、慢 ...

点击注册小程序 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 1）5/28小鹏Mona M03加推Plus和Max版本共4款全新车型上市，其中Max版本首次将双Orin+城市无图智 驾价格下探至15万元以内；新车上市1小时内大定突破1万辆，Max版本占比超80%。2）5/8理想L系列智能 焕新版正式上市，所有车型售价保持不变，AD Pro搭载芯片由地坪想J5升级至J6M、AD Max搭载芯片由 英伟达双Orin升级为Thor-U。 6月购车权益或有小幅放大可能性 特斯拉：国产Model 3交付周期维持1-3周，焕新版Model Y交付周期维持2-5周；与5月优惠相同，6/30前 Model 3后驱版及长续航全驱版享5年0息购车优惠+限时补贴8,000元、焕新版Model Y可享全系5年0息金融 政策。 ...

Core Insights - The rapid advancement of China's new energy vehicle industry is driving a transformation in vehicle power systems, particularly in battery technologies such as lithium-ion and fuel cells [1] Group 1: Battery Technology Innovations - The demand for longer range in electric vehicles necessitates an increase in battery energy density, with lithium-ion batteries nearing their theoretical limits. Lithium-rich manganese-based cathode materials are emerging as a promising solution, potentially achieving energy densities of 600-700 Wh/kg in solid-state batteries [3][5] - Sodium-ion batteries are highlighted for their long lifespan, wide temperature range, and cost-effectiveness, with the potential to enhance cargo capacity by 15% in heavy-duty applications. A new company has been established to scale up production of sodium-ion battery materials and cells [8] - Solid-state batteries are transitioning from laboratory to industrial applications, offering improved energy density and safety. Hybrid solid-liquid batteries are seen as a viable interim solution before full solid-state technology becomes mainstream [10] Group 2: Safety and Standards - The new national standards for battery safety emphasize a "zero tolerance" approach, mandating that batteries must not catch fire or explode. This includes rigorous testing protocols to ensure safety under various conditions [12][14] - Innovations in battery management systems are crucial for enhancing safety, utilizing real-time monitoring to predict and mitigate potential hazards [14] Group 3: Fuel Cell Developments - Fuel cells are recognized for their efficiency and environmental benefits, but high production costs hinder commercialization. Efforts are underway to reduce costs through domestic production of key components [20][22] - The integration and smart control of fuel cell systems are advancing, leveraging big data and AI for improved performance and reliability [22] Group 4: Market Applications and Synergies - Fuel cells are expanding into diverse applications beyond transportation, including distributed power generation and military uses, with significant advantages in energy density [24] - The complementary nature of battery and fuel cell technologies allows for innovative hybrid solutions, catering to different travel needs and enhancing overall system efficiency [25]

中信建投 医药每周谈 20250602 摘要 沛嘉医疗冲击波球囊技术国内早期临床试验显示 30%-50%疗效，经导 管主动脉瓣置换产品 Mona Q 全球 Fame 临床试验入组 9 例，长期随访 无死亡或中风，已获美国 IDE 临床许可，有望年内推进美国临床试验。 健世科技三尖瓣介入置换产品欧洲完成临床注册实验，成功率达 97%， 有望 2025 年获 CE 注册证，并计划拓展至美国市场，聚焦差异化竞争 优势。 先瑞达医疗膝下 DCB 是全球唯一基于多中心临床试验获批的膝下动脉狭 窄治疗工具，2024 年被波士顿科学收购 65%股权，借助其全球网络加 速国际推广及商业化。 赛诺医疗自膨式颅内药物支架临床数据优异，再狭窄率仅 1.7%- 1.87%，手术成功率 100%，预计今年获批，享有一年半到两年的市场 独家期。 心泰医疗封堵器类产品国内市占率领先，拥有四代可降解封堵器系列， 主动脉瓣凯卫已获批上市，一季度开始商业化植入，依托乐普资源有望 快速放量。 国产医疗器械企业如何应对海外市场竞争并实现商业化？ 国产医疗器械企业通过多种策略应对海外市场竞争并实现商业化。例如，沛嘉 医疗通过突破核心专利、进行早期临床 ...

Core Viewpoint - Despite a slowdown in revenue growth, the company has achieved positive growth in core operating metrics through excellent cost control [1][2] Group 1: Financial Performance - For Q1 2025, the company reported revenue of 1.923 billion (+12.88%), GAAP net profit of 518 million (+111.53%), adjusted net profit of 764 million (+43.93%), and adjusted operating profit of 692 million (+76.18%) with a non-GAAP operating profit margin (OPM) of 36.0% [2] - Revenue growth has slowed down, with quarterly growth rates for 2024Q1 to 2025Q1 being +33.37%, +28.85%, +18.98%, +15.40%, and +12.88% respectively [2] - The company has effectively reduced sales expense ratio by 8.46 percentage points, with absolute sales expenses decreasing by 88.05 million year-on-year; R&D expense ratio decreased by 5.42 percentage points, and management expense ratio decreased by 2.07 percentage points [2] Group 2: Future Outlook - Revenue growth is expected to continue slowing in Q2 2025, with projected revenue between 2.05 billion and 2.08 billion, representing a year-on-year increase of 6.9% to 8.5% [3] - The company has a clear and rational plan for AI product development in the human resources service sector, with products for B2B, B2C, and management already planned and clear application scenarios identified [3] - The company anticipates that these AI products will begin gray testing in Q2 to Q3 of 2025, potentially contributing to future revenue [3]

Core Viewpoint - Jiangling Motors is focusing on expanding its overseas market and advancing its transformation towards new energy and intelligent vehicles, with a positive outlook on its growth potential [1][4]. Financial Performance - In 2024, Jiangling Motors achieved a revenue of 38.374 billion yuan, a year-on-year increase of 15.70%, and a net profit attributable to shareholders of 1.537 billion yuan, up 4.17% year-on-year [2]. - For Q1 2025, the company reported a revenue of 7.967 billion yuan, a slight decrease of 0.09% year-on-year, and a net profit of 306 million yuan, down 36.56% year-on-year [2]. Revenue Breakdown - In 2024, the company's vehicle revenue reached 34.702 billion yuan, a year-on-year increase of 14.32%, with steady growth in SUV, pickup, and light bus sales [3]. - Parts revenue was 1.807 billion yuan, up 5.04% year-on-year, while sales of materials and others surged to 1.138 billion yuan, a 130.73% increase [3]. Profitability Metrics - The gross margin for 2024 was 14.13%, down 1.25 percentage points year-on-year, while the net margin was 3.14%, a decrease of 0.07 percentage points [3]. - In Q1 2025, the gross margin was 11.81%, down 0.48 percentage points year-on-year, and the net margin was 3.88%, an increase of 0.88 percentage points [3]. International Market Expansion - Jiangling Motors' export volume reached 116,600 units in 2024, a year-on-year increase of 21.9%, with over 100 overseas dealers and showrooms [4]. - The company has signed a vehicle export cooperation framework agreement with Ford, expanding its product reach to 105 countries [4]. New Energy Strategy - The company has fully covered the light commercial vehicle, light truck, and pickup segments in its new energy product line, achieving sales of 10,900 new energy vehicles and generating revenue of 1.118 billion yuan [4]. - New electric models like the E-Fushun and E-Shund are enhancing the company's electric commercial vehicle offerings [4]. Intelligent Connectivity Initiatives - Jiangling Motors is collaborating with various tech companies to develop smart driving and connected vehicle technologies, including a successful L4-level road test license in Guangzhou [5]. Investment Outlook - Short-term growth is expected as the company increases its focus on new energy and overseas markets, with key models gradually being released [6]. - Long-term prospects are positive, with anticipated breakthroughs in new energy and L4-level autonomous driving technologies [6]. - Revenue projections for 2025-2027 are 42.439 billion, 48.208 billion, and 55.728 billion yuan, with net profits of 1.6 billion, 1.849 billion, and 2.187 billion yuan respectively [6].

导读 ： 荣耀进军机器人赛道；多家公司加速布局Robotaxi ； 解锁【第一财经智享会员】实时解读 市场动态，把握投资先机。 【第一财经智享会员专属】 【 今 日 速 读 】 精选行业研报，助您捕捉行业风口 【精选快读】 1 .荣耀进军机器人赛道，关注产业链带来的增量机遇 5月2 8日晚间，荣耀CEO李健在回应进军机器人赛道时表示，机器人无疑是公司重点关注的核心赛 道。"我们的核心思路围绕不同场景与用户需求展开，若特定场景需要与相关厂商合作，我们会以 开放姿态推进，同时，荣耀具备自主技术实力，包括长期积累的硬件研发能力与算法优势，这些自 主可控的技术足以支撑新产业的自主开发。" 2025.05.30 点击一键解锁 2. 国内外公司纷纷加码，Robotaxi商业化有望提速 近期，特斯拉、小马智行等多家国内外公司纷纷发布有关Ro b o t a x i的计划。 在当晚的荣耀4 0 0系列发布会上，荣耀展示了一款机器人，跑步速度已经达到4m/s，打破了之前的 机器人行业记录。 万联证券表示，人形机器人产业正处于技术突破与商业化落地的关键节点，政策支持、入局者不断 增加及AI大模型赋能共同推动行业加速发展，2 0 ...

【导读】宇树科技更名 5月29日，据证券时报消息，宇树科技向合作伙伴发布通知称，因公司发展需要，杭州宇树科技有限公司即日起名称变更为杭州宇树科技股份有限公司。 届时，原公司所有业务由新公司名称继续经营，原公司签订的所有合同继续有效。 此番变更引起市场猜测，宇树科技或在为启动上市做准备。对此，中国基金报记者向宇树科技相关工作人员求证，对方表示，目前没有更多消息可对外发 布。 背后多达38位股东 天眼查显示，宇树科技已完成9轮融资，投资方包括美团、顺为资本、红杉中国、中信证券、北京机器人产业发展投资基金等38家创投机构。去年9月的C 轮融资完成后，估值约80亿元。 从目前的持股结构来看，创始人王兴兴持股27.8%；美团持股8.25%，是其最大的外部股东；红杉中国持股7.13%，为第三大股东。值得注意的是，红杉中 国从Pre-A轮进入，还参与了Pre-A+轮和C轮的融资，是少有一直坚定持有的早期投资机构之一。 | | 股东信息 ● ■ 品股权结构 | VIP | | | | | 品 数据纠错 | 心天眼查 | | --- | --- | --- | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The company has established a clear strategy of "innovation + overseas commercialization" and has achieved significant results through five years of careful planning [1] Group 1: Overseas Commercialization Strategy - The company's overseas commercialization strategy focuses on high-quality Chinese pharmaceuticals entering global markets, emphasizing "global selection and global coverage" [2] - The 2.0 strategy includes expanding from emerging markets to the EU, transitioning from biosimilars to high-end complex injectable formulations, and localizing operations [2] - The company aims to enhance its international competitiveness by upgrading product structures and establishing a strong localized operational network in key global markets such as Brazil, Mexico, and Germany [2] Group 2: Innovation and Clinical Development - The company is committed to completing a certain number of innovative drug clinical applications in the US and China each year to accelerate the internationalization of its product pipeline [2] - The company is strengthening its business development capabilities by forming specialized teams in China and Europe and actively seeking deep collaborations with leading global pharmaceutical companies [2] - Several innovative drug projects are currently in the negotiation stage, and the company is increasing its academic exchanges to enhance its international influence in innovative drug research [2] Group 3: Future Growth and Market Expansion - The company has laid a solid foundation for its overseas commercialization strategy since its establishment in 2021, with good sales performance of its albumin paclitaxel product in the EU market [3] - The company plans to introduce new products and drive sales through its established overseas commercialization platform, aiming for long-term business growth [3] - The company targets a 200%-400% increase in export revenue by 2025 compared to 2023, as outlined in its 2024 equity incentive plan [3]